Pfizer (PFE Quick QuotePFE - Free Report) reported $16.58 billion in revenue for the quarter ended September 2026, representing a year-over-year decline of 0.4%. EPS of $0.87 for the same period compares to $0.87 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $16.13 billion, representing a surprise of +2.8%. The company delivered an EPS surprise of +20.83%, with the consensus EPS estimate being $0.72.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Pfizer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Primary Care- Abrysvo- United States: $141 million versus the two-analyst average estimate of $185.25 million. The reported number represents a year-over-year change of -32.9%.
• Revenues- Primary Care- Comirnaty- Total International: $246 million compared to the $153.95 million average estimate based on two analysts. The reported number represents a change of -12.8% year over year.
• Revenues- Oncology- Talzenna- United States: $41 million versus the two-analyst average estimate of $41.48 million. The reported number represents a year-over-year change of +24.2%.
• Revenues- Oncology- Talzenna- Total International: $18 million compared to the $18.4 million average estimate based on two analysts. The reported number represents a change of +28.6% year over year.
• Revenues- Oncology- Ibrance- Worldwide: $1.08 billion compared to the $1.03 billion average estimate based on two analysts. The reported number represents a change of +2.4% year over year.
• Revenues- Specialty Care- Xeljanz- Worldwide: $213 million compared to the $160.05 million average estimate based on two analysts. The reported number represents a change of -32% year over year.
• Revenues- Specialty Care- Inflectra- Worldwide: $186 million versus the two-analyst average estimate of $141.2 million. The reported number represents a year-over-year change of +7.5%.
• Revenues- Primary Care- Eliquis- Worldwide: $2.52 billion compared to the $2.38 billion average estimate based on two analysts. The reported number represents a change of +25.2% year over year.
• Revenues- Pfizer CentreOne- Worldwide: $300 million compared to the $339.83 million average estimate based on two analysts. The reported number represents a change of -12.8% year over year.
• Revenues- Pfizer Biopharma- Worldwide: $16.28 billion compared to the $15.6 billion average estimate based on two analysts. The reported number represents a change of -0.2% year over year.
• Revenues- Specialty Care- Vyndaqel family- Worldwide: $1.77 billion compared to the $1.68 billion average estimate based on two analysts. The reported number represents a change of +11.4% year over year.
• Revenues- Primary Care- Comirnaty- Worldwide: $808 million compared to the $775.86 million average estimate based on two analysts. The reported number represents a change of -29.8% year over year.

View all Key Company Metrics for Pfizer here>>>

Shares of Pfizer have returned +11.9% over the past month versus the Zacks S&P 500 composite's -2.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.